Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4467MR)

This product GTTS-WQ4467MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ4467MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5220MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ7005MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ8019MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GZ-402668
GTTS-WQ15345MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ4421MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-663513
GTTS-WQ1097MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ11648MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MGD-013
GTTS-WQ693MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA A-1230717
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW